Kiniksa Pharmaceuticals Ltd

Noticias y eventos de Kiniksa Pharmaceuticals Ltd (KNSA)

$92.240

-5.027 (-5.45%)Al cierre

Noticias de KNSA

Eventos de KNSA

10/27 12:30

Kiniksa Shares Rise 20.4% to $87.88

Kiniksa is up 20.4%, or $14.90 to $87.88.

10/27 10:30

Kiniksa Shares Rise 16.5% to $85.01

Kiniksa is up 16.5%, or $12.03 to $85.01.

10/27 08:00

Kiniksa Reports Q3 Revenue of $285.97M, Beating Expectations

Reports Q3 revenue $285.97M, consensus $260.61M. "Kiniksa continues to build a leading IL-1alpha and IL-1beta inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year," said Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa. "Our robust financial position supports continued investment in value creation through ARCALYST, KPL-387, and KPL-1161. We now expect 2026 ARCALYST net sales of between $1.045 and $1.050 billion, up from our previous range of between $980 and $995 million. Additionally, we continue to enroll and dose patients in PASTORALE, the pivotal Phase 3 trial of KPL-387 evaluating once monthly subcutaneous dosing. We expect data in the second half of 2027, with the goal of bringing this important treatment option to patients in the 2028/2029 timeframe. We remain on track to initiate a Phase 1 trial of KPL-1161 by the end of this year."

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar